Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

SARS-CoV-2 variants and ending the COVID-19 pandemic

Fontanet, A. L., Autran, B., Lina, B., Kiény, M. P., Karim, S. S. A., & Sridhar, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00370-6 · Cited by 513 · see citing works

The first 12 months of COVID-19: a timeline of immunological insights

Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 448 · see citing works

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Martínez-Flores, D., Zepeda–Cervantes, J., Cruz-Reséndiz, A., Aguirre‐Sampieri, S., Sampieri, A., & Vaca, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701501 · Cited by 237 · see citing works

A paper-based assay for the colorimetric detection of SARS-CoV-2 variants at single-nucleotide resolution

Zhang, T., Deng, R., Wang, Y., Wu, C., Zhang, K., Wang, C., Gong, N., Ledesma‐Amaro, R., Teng, X., Yang, C., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00907-0 · Cited by 207 · see citing works

Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York

Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., et al. (2021) · doi:10.1101/2021.02.23.21252259

Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis

Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 116 · see citing works

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations

He, Q., Mao, Q., Zhang, J., Bian, L., Gao, F., Wang, J., Xu, M., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669339 · Cited by 108 · see citing works

Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion

Salleh, M. Z., Derrick, J. P., & Deris, Z. Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147425 · Cited by 79 · see citing works

A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development

Abdulla, Z. A., Al-Bashir, S. M., Al-Salih, N. S., Aldamen, A. A., & Abdulazeez, M. Z. (2021) · Pathogens · doi:10.3390/pathogens10070788 · Cited by 59 · see citing works

Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape

Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 50 · see citing works

Profiles of current COVID-19 vaccines

Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 45 · see citing works

Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging

Flores-Alanis, A., Cruz‐Rangel, A., Rodríguez‐Gómez, F., González, J., Torres-Guerrero, C. A., Delgado, G., Cravioto, A., & Morales-Espinosa, R. (2021) · Pathogens · doi:10.3390/pathogens10020184 · Cited by 38 · see citing works

Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic

Yavarian, J., Nejati, A., Salimi, V., Shafiei-Jandaghi, N.-Z., Sadeghi, K., Abedi, A., Sharifi‐Zarchi, A., Gouya, M. M., & Mokhtari‐Azad, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267847 · Cited by 34 · see citing works

SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape

Yang, L., Li, J., Guo, S., Hou, C., Liao, C., Shi, L., Ma, X., Jiang, S., Zheng, B., Fang, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212114 · Cited by 35 · see citing works

Evolution of Antiviral Drug Resistance in SARS-CoV-2

Dinata, R., Baindara, P., & Mandal, S. M. (2025) · Viruses · doi:10.3390/v17050722 · Cited by 29 · see citing works

COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants

Noor, R., Shareen, S., & Billah, M. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00787-z · Cited by 27 · see citing works

Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition

Kramer, K. J., Johnson, N., Shiakolas, A. R., Suryadevara, N., Periasamy, S., Raju, N., Williams, J. K., Wrapp, D., Zost, S. J., Walker, L. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109784 · Cited by 26 · see citing works

Potential SARS-CoV-2 vaccines: Concept, progress, and challenges

Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 21 · see citing works

Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models

Yang, H., Cao, J. A., Lin, X., Yue, J., Zieneldien, T., Kim, J., Wang, L., Fang, J., Huang, R., Bai, Y., et al. (2022) · Viruses · doi:10.3390/v14030449 · Cited by 17 · see citing works

Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidatePreprint

Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15 · see citing works

Corilagin and 1,3,6-Tri- O -galloy-β- d -glucose: potential inhibitors of SARS-CoV-2 variants

Binette, V., Côté, S., Haddad, M., Nguyen, P. T., Bélanger, S., Bourgault, S., Ramassamy, C., Gaudreault, R., & Mousseau, N. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01790j · Cited by 16 · see citing works

Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation

Kostaki, E. G., Tseti, I. K., Tsiodras, S., Pavlakis, G. N., Sfikakis, P. P., & Paraskevis, D. N. (2021) · Life · doi:10.3390/life11050375 · Cited by 13 · see citing works

Relationship between blood clots and COVID-19 vaccines: A literature review

Atyabi, S. M. H., Rommasi, F., Ramezani, M. H., Ezabadi, M. F. G., Arani, M. A., Sadeghi, M. H., Ahmed, M. M., Rajabi, A., Dehghan, N., Sohrabi, A., et al. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0035 · Cited by 12 · see citing works

Generation and Effect Testing of a SARS-CoV-2 RBD-Targeted Polyclonal Therapeutic Antibody Based on a 2-D Airway Organoid Screening System

He, Y., Qu, J. T., Wei, L., Liao, S., Zheng, N., Liu, Y., Wang, X., Jing, Y., Shen, C. K.-F., Ji, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689065 · Cited by 11 · see citing works

Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines

Dubé, C., Paris‐Robidas, S., Andreani, G., Gutzeit, C., D’Aoust, M., Ward, B. J., & Trépanier, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.046 · Cited by 11 · see citing works

Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants

Ballesteros-Sanabria, L., Pelaez-Prestel, H. F., Ras-Carmona, A., & Reche, P. A. (2022) · Biomedicines · doi:10.3390/biomedicines10050996 · Cited by 9 · see citing works

mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2

Noor, R. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01168-3 · Cited by 9 · see citing works

A review on the induction of host immunity by the current COVID-19 vaccines and a brief non-pharmaceutical intervention to mitigate the pandemic

Noor, R. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00719-x · Cited by 7 · see citing works

How do the severe acute respiratory coronavirus 2 (SARS-CoV-2) and its variants escape the host protective immunity and mediate pathogenesis?

Noor, R. (2022) · Bulletin of the National Research Centre · doi:10.1186/s42269-022-00945-3 · Cited by 2 · see citing works

Hydrophobic interaction determines docking affinity of SARS CoV 2 variants with antibodiesPreprint

Li, J., Hou, C., Wang, M., Liao, C.-Y., Guo, S., Shi, L., Ma, X., Zhang, H., Jiang, S., Zheng, B., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2103.00399 · Cited by 4 · see citing works

Covid19 and its vaccines

Shreya, C., Prasad, M. A. G., & Sekharan, C. B. (2021) · Caribbean Journal of Science and Technology · doi:10.55434/cbi.2021.9108 · Cited by 1 · see citing works

Different Potential Vaccine Candidates of Covid-19 Diseases and their Immunological Aspect

Abebe, B. M. (2023) · Vaccines & Vaccination Open Access · doi:10.23880/vvoa-16000160 · Cited by 1 · see citing works

Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine

Singh, A. P., & Kumar, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1997487

Profilaxia specifică a infecției cu SARS-COV-2, între clasic și modern | [Specific prophylaxis of SARS-COV-2 infection, between classical and modern]

Constantinescu, E. M., & Constantinescu, C.-A. (2022) · Jurnal Medical Brasovean · doi:10.31926/jmb.2021.1.5

Use of Phraseological Units in Coronavirus Articles on the Basis of English Mass Media

Lazarieva, I., & Chulanova, H. V. (2021) · Вісник Маріупольського державного гуманітарного університету. Сер.: Філологія · doi:10.34079/2226-3055-2021-14-25-191-200

Mikroorganismen: Von Bakterien bis Prionen

Gey, M. H. (2023) · Springer eBooks · doi:10.1007/978-3-662-67650-9_5

Time series analysis on Alpha, Delta, and Omicron waves of COVID-19 infections in Indian provincesPreprint

Yadav, S. K., Mehra, M., Mishra, H. R., & Akhter, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-2412128/v1

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n296 · Cited by 235 · see citing works

Novavax offers first evidence that COVID vaccines protect people against variants

Callaway, E., & Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-00268-9 · Cited by 107 · see citing works

The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose

Sacks, H. S. (2021) · Annals of Internal Medicine · doi:10.7326/acpj202111160-124 · Cited by 7 · see citing works

In adults who had not had COVID-19, Novavax vaccine had 90% efficacy at ≥7 d after the second dose

Granwehr, B. P. (2022) · Annals of Internal Medicine · doi:10.7326/j22-0028 · Cited by 5 · see citing works

Daily briefing: Novavax vaccine is highly effective — and practical

Graham, F. (2021) · Nature · doi:10.1038/d41586-021-01623-6